Annovis Bio

Buntanetap is an investigational oral therapy that represents a fundamentally different approach to treating neurodegenerative diseases. Rather than targeting a single pathological protein, buntanetap uses a selective RNA-targeting mechanism to inhibit the translation of multiple neurotoxic proteins simultaneously, including amyloid precursor protein (APP), amyloid-beta, tau, alpha-synuclein, and TDP-43. This multi-target approach addresses a critical gap in the field: traditional single-target drugs have shown limited efficacy because neurodegenerative diseases involve multiple pathological proteins acting in concert. Buntanetap acts upstream of protein synthesis, preventing the production of multiple disease-relevant species before they accumulate or misfold. The drug is administered once daily orally, enabling long-term patient compliance compared to parenteral therapies. This translational control mechanism is distinct from immunotherapies targeting amyloid or tau, or enzyme inhibitors targeting single pathways. By addressing the fundamental problem of polyprotein pathology, buntanetap's mechanism offers potential advantages for disease modification across multiple neurodegenerative conditions. The company's clinical data in Parkinson's disease showed meaningful improvements across cognitive and motor measures, with particular benefit on cognitive endpoints—a finding consistent with buntanetap's multi-protein mechanism. This rationale supports the company's expansion to additional indications including Parkinson's disease dementia.

Annovis Bio's clinical development of buntanetap has generated evidence supporting advancement to pivotal Phase III studies in both Alzheimer's disease and Parkinson's disease. In Parkinson's disease, the completed Phase III trial enrolled four hundred seventy-one patients with early disease and demonstrated clinically meaningful improvements across key MDS-UPDRS (Movement Disorder Society Unified Parkinson's Disease Rating Scale) measures, the standard instrument for assessing Parkinson's disease severity. Notably, buntanetap halted cognitive decline in trial participants, a finding of particular significance given the cognitive impairment present in Parkinson's disease. Biomarker analyses revealed that Parkinson's disease patients with amyloid co-pathology—a subset often showing accelerated cognitive decline—benefited particularly from buntanetap treatment, supporting the multi-protein mechanism hypothesis. In Alzheimer's disease, the ongoing pivotal Phase III study (NCT06709014) employs a dual-endpoint design with enrollment of seven hundred sixty patients with early disease and biomarker-confirmed amyloid pathology. As of March 2026, enrollment has reached sixty-five percent across eighty-three U.S. clinical sites. The trial's six-month readout will evaluate symptomatic efficacy expected in early two thousand twenty-seven, with the eighteen-month disease-modifying readout anticipated in early two thousand twenty-eight. In February 2026, the Data and Safety Monitoring Board provided a positive safety recommendation at the six-month interim evaluation, supporting trial continuation without modifications—a significant milestone affirming buntanetap's tolerability profile at six months of exposure. Novel biomarker data presented by Annovis have demonstrated that buntanetap reduces biomarkers of neuronal damage in Alzheimer's disease patients, supporting the potential for disease-modifying activity. These data collectively indicate that buntanetap exhibits both symptomatic benefit (particularly on cognitive measures) and potential disease-modifying effects through reduction of pathological protein accumulation.

Annovis Bio's lead candidate buntanetap is currently in pivotal Phase III clinical development for Alzheimer's disease and has completed Phase III development in Parkinson's disease with plans for an Open-Label Extension. The regulatory pathway for Alzheimer's disease is well-defined: the company's pivotal Phase III study is designed with dual endpoints addressing both symptomatic and disease-modifying efficacy. The symptomatic efficacy readout is anticipated in early two thousand twenty-seven, with the disease-modifying readout expected in early two thousand twenty-eight. If positive efficacy results are obtained at these readouts and accepted by the FDA, Annovis would be positioned to file a Biologic License Application (BLA) or New Drug Application (NDA) in two thousand twenty-seven or two thousand twenty-eight depending on the timing and magnitude of benefit observed. For Parkinson's disease, the company has completed Phase III enrollment and is now characterizing longer-term effects through an Open-Label Extension study that commenced in January two thousand twenty-six. This extension study will include both previous trial participants and de novo patients who have undergone deep brain stimulation (DBS) for at least twelve months. For the emerging Parkinson's disease dementia indication, the FDA granted Annovis a Type C meeting in January two thousand twenty-six to discuss the development pathway. Following this meeting, the company received positive FDA feedback to proceed with a dedicated Phase III study in Parkinson's disease dementia. The timelines for initiating and completing this trial remain to be determined, but the FDA's constructive stance supports advancement. Overall, buntanetap's regulatory trajectory is favorable with clear FDA alignment on development pathways across multiple indications and potential for regulatory submissions beginning in two thousand twenty-seven.

Annovis Bio generates no revenue from product sales and relies entirely on equity financing to fund its operations and clinical development programs. The company has completed multiple capital raises since its founding in two thousand eight as QR Pharma. In January two thousand twenty, when the company went public on the NYSE American exchange, it raised fourteen million dollars in initial public offering proceeds. The company has continued to access capital markets for subsequent financing needs. In two thousand twenty-six, Annovis announced a public offering of twenty-one million dollars structured as unit offerings combining common shares and five-year warrants, priced at four dollars per share with warrants exercisable at five dollars per share. Historical funding has involved private venture investors including Bank of America Merrill Lynch, ThinkEquity, Metalmark Capital, Robin Hood Ventures, and Delaware Crossing Investment Group, among others. The company has raised a total of approximately eleven million eight hundred eighty thousand dollars through its equity history prior to becoming public. Following the two thousand twenty public listing and subsequent two thousand twenty-six capital raise, the company has access to capital markets for periodic equity financing to extend its clinical development runway. As a clinical-stage biotech with no near-term revenue, Annovis must periodically access equity capital to fund ongoing Phase III trials, regulatory activities, and corporate operations. The company's cash runway is contingent on burn rate (operating expenses) and the timing of data readouts that could trigger milestone-based financing or strategic partnerships. As Phase III trials are capital-intensive, the company will likely require periodic additional capital raises through two thousand twenty-seven and beyond as it moves toward potential regulatory submissions.

Annovis Bio has established key research and clinical collaborations that enhance its scientific capabilities and clinical trial infrastructure. The company entered into a Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging (NIA), part of the National Institutes of Health, to collaborate on developing and validating pharmacodynamic biomarkers for buntanetap. This partnership specifically focuses on isolating and characterizing brain-derived extracellular vesicles (EVs) in blood plasma that may serve as non-invasive biomarkers reflecting neuronal function and viability. Such biomarker development is scientifically important for understanding buntanetap's effects in human subjects and may inform future patient selection, trial design, or clinical monitoring strategies. The partnership leverages NIA's expertise in neurodegenerative disease biology and biomarker research while advancing Annovis's translational program. Annovis is conducting a Phase IIa Alzheimer's disease study in collaboration with the Alzheimer Disease Cooperative Study (ADCS) group, a well-established academic network with decades of experience conducting Alzheimer's disease clinical research. This collaboration provides access to patient populations and leverages ADCS's extensive trial infrastructure and expertise. The company also maintains an active dialogue with the FDA regarding its clinical development pathways. The company received FDA alignment meetings in January two thousand twenty-six regarding its Parkinson's disease dementia program and reaffirmed FDA alignment on the pivotal Phase III Alzheimer's disease study design. This regulatory engagement ensures that the company's development strategy aligns with FDA expectations for efficacy endpoints, patient selection, and data packages. While Annovis does not currently have major pharmaceutical licensing or co-development partnerships, the company's engagement with academic research institutions and government agencies positions it favorably for potential future collaborations in areas such as commercialization, co-promotion, or expanded clinical development as the company advances toward potential regulatory milestones.

Annovis Bio is led by Maria L. Maccecchini, Ph.D., who serves as Founder, President, and Chief Executive Officer. Dr. Maccecchini is a scientist, serial entrepreneur, and angel investor who founded the company in two thousand eight with the explicit mission of developing disease-modifying treatments for Alzheimer's disease, Parkinson's disease, and related neurodegenerative conditions. Her personal motivation stems from witnessing her mother's battle with Alzheimer's disease, an experience that crystallized her commitment to the field. Dr. Maccecchini brings substantial industry experience across multiple sectors of pharmaceutical development. She previously served as Chief Executive Officer of Symphony Pharmaceuticals, where she led clinical-stage drug development operations. Before Symphony, she was General Manager of Bachem Bioscience, the United States subsidiary of Bachem AG of Switzerland, a major pharmaceutical contract manufacturer. In this role, she gained deep expertise in pharmaceutical manufacturing, scale-up, and chemical development. Earlier in her career, Dr. Maccecchini served as Head of Molecular Biology at Mallinckrodt Pharmaceuticals, one of the largest global pharmaceutical companies, where she developed hands-on knowledge of molecular biology, drug mechanism research, and large-organization pharmaceutical operations. Dr. Maccecchini's career trajectory demonstrates sustained executive leadership in complex biotechnology and pharmaceutical environments, with particular expertise in bringing drugs from discovery through clinical development. Beyond Annovis, she serves on the board of directors of Lantern Pharma, another biotechnology company. As of March two thousand twenty-six, following the departure of Chief Financial Officer Mark Guerin, Dr. Maccecchini assumed the additional role of Acting Chief Financial Officer while the board searches for a permanent successor. This consolidation reflects the lean operational structure typical of clinical-stage companies and Dr. Maccecchini's hands-on engagement with all critical business functions.

Annovis Bio's differentiation in the neurodegenerative disease market rests on its multi-protein targeting strategy and the particular mechanism of action embodied in buntanetap. While competitors in the Alzheimer's disease space focus primarily on amyloid-beta or tau—either as immunotherapy targets or through enzyme inhibition—buntanetap simultaneously addresses amyloid-beta, tau, alpha-synuclein, and TDP-43 through translational inhibition. This approach is rooted in the recognition that neurodegenerative diseases involve multiple pathological proteins acting in concert, and that targeting only a single protein has proven insufficient for meaningful clinical benefit. Recent monoclonal antibodies targeting amyloid (such as aducanumab, lecanemab, and donanemab) have demonstrated modest symptomatic slowing of cognitive decline in early Alzheimer's disease, yet effects are incremental and require expensive intravenous infusion infrastructure. Buntanetap, administered orally once daily, offers a distinctly different approach. In the Parkinson's disease space, treatment options remain limited primarily to dopamine replacement and symptomatic management. Few disease-modifying therapies exist. Annovis's demonstration that buntanetap halts cognitive decline in Parkinson's disease patients—particularly those with amyloid co-pathology—represents a potentially unique clinical benefit in a space with unmet needs for cognitive preservation. The company's willingness to pursue biomarker-enriched trial designs (enrolling only amyloid-positive patients) reflects sophisticated understanding of patient stratification and the pathological heterogeneity within diagnostic categories. Competitors vary in their approaches: some pursue single-target monoclonal antibodies, others target tau tangles, and still others focus on neuroinflammation or neuroprotection. Buntanetap's multi-protein mechanism and oral administration represent a distinct competitive positioning. The clinical data supporting halted cognitive decline in Parkinson's disease and the FDA's receptiveness to a dedicated Parkinson's disease dementia program indicate that regulators and the field view Annovis's polyprotein approach as addressing a genuine unmet medical need in neurodegenerative disease treatment.